– USA, FL – CONMED Corporation (NYSE: CNMD) announced the appointment of Kim Kelderman to its Board of Directors effective September 8, 2025.
About Kim Kelderman
Kim Kelderman has been President, CEO, and member of the Board of Bio-Techne (NASDAQ: TECH) since February 2024, having joined Bio-Techne in April 2018 as President, Diagnostics and Genomics, and having served as COO from November 2023 to January 2024. Before Bio-Techne, he was employed at Thermo Fisher Scientific, where he led three different businesses of increasing scale and complexity. Kim Kelderman managed the Platforms and Content of the Genetic Sciences Division, where he was responsible for the Instrumentation, Software, Consumables, and Assays businesses, and brands such as Applied Biosystems and legacy Affymetrix.
Before joining Thermo Fisher, Kim Kelderman served as Senior Segment Leader at Becton Dickinson, managing the global Blood Tubes “Vacutainer” business.
Kim Kelderman holds a Bachelor of Science degree from Hogeschool Heerlen of Applied Sciences in the Netherlands.
About CONMED Corporation
CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology.
For more: https://www.conmed.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.